These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

182 related articles for article (PubMed ID: 30384014)

  • 1. Update of survival and cost of metastatic melanoma with new drugs: Estimations from the MelBase cohort.
    Kandel M; Allayous C; Dalle S; Mortier L; Dalac S; Dutriaux C; Leccia MT; Guillot B; Saiag P; Lacour JP; Legoupil D; Lesimple T; Aubin F; Beylot-Barry M; Brunet-Possenti F; Arnault JP; Granel-Brocard F; Stoebner PE; Dupuy A; Maubec E; Grob JJ; Dreno B; Rotolo F; Ballon A; Michiels S; Lebbe C; Borget I
    Eur J Cancer; 2018 Dec; 105():33-40. PubMed ID: 30384014
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Hospitalisation costs of metastatic melanoma in France; the MELISSA study (MELanoma In hoSpital coSts Assessment).
    Fernandes J; Bregman B; Combemale P; Amaz C; de Léotoing L; Vainchtock A; Gaudin AF
    BMC Health Serv Res; 2017 Aug; 17(1):542. PubMed ID: 28789648
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Management of glioblastoma: comparison of clinical practices and cost-effectiveness in two cohorts of patients (2008 versus 2004) diagnosed in a French university hospital.
    Diebold G; Ducray F; Henaine AM; Frappaz D; Guyotat J; Cartalat-Carel S; Breant V; Fouquet A; Aulagner G; Honnorat J; Armoiry X
    J Clin Pharm Ther; 2014 Dec; 39(6):642-8. PubMed ID: 25164371
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Quality-of-life assessment in French patients with metastatic melanoma in real life.
    Kandel M; Dalle S; Bardet A; Allayous C; Mortier L; Dutriaux C; Guillot B; Leccia MT; Dalac S; Legoupil D; Saiag P; Montaudie H; Arnault JP; Brunet-Possenti F; Grob JJ; DeQuatrebarbes J; Beylot-Barry M; Lesimple T; Aubin F; Maubec E; Granel-Brocard F; Stoebner PE; Dupuy A; Dreno B; Michiels S; Lebbe C; Borget I
    Cancer; 2020 Feb; 126(3):611-618. PubMed ID: 31639198
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A Population-based Study of Survival Impact of New Targeted and Immune-based Therapies for Metastatic or Unresectable Melanoma.
    Hanna TP; Nguyen P; Baetz T; Booth CM; Eisenhauer E
    Clin Oncol (R Coll Radiol); 2018 Oct; 30(10):609-617. PubMed ID: 30196844
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Accounting for Cured Patients in Cost-Effectiveness Analysis.
    Othus M; Bansal A; Koepl L; Wagner S; Ramsey S
    Value Health; 2017 Apr; 20(4):705-709. PubMed ID: 28408015
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Potential health gains for patients with metastatic renal cell carcinoma in daily clinical practice: A real-world cost-effectiveness analysis of sequential first- and second-line treatments.
    De Groot S; Blommestein HM; Redekop WK; Sleijfer S; Kiemeney LALM; Oosterwijk E; Uyl-de Groot CA
    PLoS One; 2017; 12(5):e0177364. PubMed ID: 28531203
    [TBL] [Abstract][Full Text] [Related]  

  • 8. More than 5000 patients with metastatic melanoma in Europe per year do not have access to recommended first-line innovative treatments.
    Kandolf Sekulovic L; Peris K; Hauschild A; Stratigos A; Grob JJ; Nathan P; Dummer R; Forsea AM; Hoeller C; Gogas H; Demidov L; Lebbe C; Blank C; Olah J; Bastholt L; Herceg D; Neyns B; Vieira R; Hansson J; Rutkowski P; Krajsova I; Bylaite-Bucinskiene M; Zalaudek I; Maric-Brozic J; Babovic N; Banjin M; Putnik K; Weinlich G; Todorovic V; Kirov K; Ocvirk J; Zhukavets A; Kukushkina M; De La Cruz Merino L; Ymeri A; Risteski M; Garbe C
    Eur J Cancer; 2017 Apr; 75():313-322. PubMed ID: 28264791
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cost-effectiveness of everolimus for second-line treatment of metastatic renal cell carcinoma in Serbia.
    Mihajlović J; Pechlivanoglou P; Sabo A; Tomić Z; Postma MJ
    Clin Ther; 2013 Dec; 35(12):1909-22. PubMed ID: 24238790
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Trends in survival and costs in metastatic melanoma in the era of novel targeted and immunotherapeutic drugs.
    Franken MG; Leeneman B; Aarts MJB; van Akkooi ACJ; van den Berkmortel FWPJ; Boers-Sonderen MJ; van den Eertwegh AJM; de Groot JWB; Hospers GAP; Kapiteijn E; Piersma D; van Rijn RS; Suijkerbuijk KPM; van der Veldt AAM; Westgeest HM; Wouters MWJM; Haanen JBAG; Uyl-de Groot CA
    ESMO Open; 2021 Dec; 6(6):100320. PubMed ID: 34856511
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparative healthcare costs in patients with metastatic melanoma in the USA.
    Chang CL; Schabert VF; Munakata J; Donga P; Abhyankar S; Reyes CM; Yim YM
    Melanoma Res; 2015 Aug; 25(4):312-20. PubMed ID: 25882026
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Current trends in the management of glioblastoma in a French University Hospital and associated direct costs.
    Henaine AM; Paubel N; Ducray F; Diebold G; Frappaz D; Guyotat J; Cartalat-Carel S; Aulagner G; Hartmann D; Honnorat J; Armoiry X
    J Clin Pharm Ther; 2016 Feb; 41(1):47-53. PubMed ID: 26748577
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Economic impact of healthcare resource utilisation patterns among patients diagnosed with advanced melanoma in the United Kingdom, Italy, and France: results from a retrospective, longitudinal survey (MELODY study).
    Johnston K; Levy AR; Lorigan P; Maio M; Lebbe C; Middleton M; Testori A; Bédane C; Konto C; Dueymes A; Sbarigia U; van Baardewijk M
    Eur J Cancer; 2012 Sep; 48(14):2175-82. PubMed ID: 22480965
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Real-world costs and outcomes in metastatic renal cell carcinoma patients treated with targeted therapies: a cohort study from the French health insurance database.
    Maroun R; Fleury L; Nachbaur G; Maunoury F; Vanhille JL; Durand-Zaleski I
    Curr Med Res Opin; 2017 Oct; 33(10):1755-1762. PubMed ID: 28748721
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Costs associated with adverse events for systemic therapies in metastatic melanoma.
    Fu AZ; Li Z; Tang J; Mahmood S; Whisman T; Qiu Y
    J Comp Eff Res; 2018 Sep; 7(9):867-879. PubMed ID: 30192155
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Economic analysis of adjuvant therapy with interferon alpha-2a in stage II malignant melanoma.
    Lafuma A; Dreno B; Delaunay M; Emery C; Fagnani F; Hieke K; Bonerandi JJ; Grob JJ;
    Eur J Cancer; 2001 Feb; 37(3):369-75. PubMed ID: 11239759
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Management of relapsed or refractory multiple myeloma in French hospitals and estimation of associated direct costs: a multi-centre retrospective cohort study.
    Armoiry X; Fagnani F; Benboubker L; Facon T; Fermand JP; Hulin C; Moreau P; Aulagner G
    J Clin Pharm Ther; 2011 Feb; 36(1):19-26. PubMed ID: 21198717
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cost and economic burden of adverse events associated with metastatic melanoma treatments in five countries.
    Vouk K; Benter U; Amonkar MM; Marocco A; Stapelkamp C; Pfersch S; Benjamin L
    J Med Econ; 2016 Sep; 19(9):900-12. PubMed ID: 27123564
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Health Care Resource Utilization and Associated Costs Among Metastatic Cutaneous Melanoma Patients Treated with Ipilimumab (INTUITION Study).
    McArthur GA; Mohr P; Ascierto PA; Arance A; Banos Hernaez A; Kaskel P; Weichenthal M; Shinde R; Stevinson K
    Oncologist; 2017 Aug; 22(8):951-962. PubMed ID: 28526721
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Survival of melanoma patients treated with targeted therapy and immunotherapy after systematic upfront control of brain metastases by radiosurgery.
    Gaudy-Marqueste C; Dussouil AS; Carron R; Troin L; Malissen N; Loundou A; Monestier S; Mallet S; Richard MA; Régis JM; Grob JJ
    Eur J Cancer; 2017 Oct; 84():44-54. PubMed ID: 28783540
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.